[1]徐 源,金春林,宋 捷,等.精神类药品集中带量采购的执行现状与政策优化[J].卫生经济研究,2024,41(06):34-38.
　XU Yuan,JIN Chunlin,SONG Jie,et al.Implementation Status and Policy Optimization of Centralized Volume-based Procurement of Psychotropic Drugs[J].Journal Press of Health Economics Research,2024,41(06):34-38.
点击复制

精神类药品集中带量采购的执行现状与政策优化
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年06期
页码:
34-38
栏目:
药械管理
出版日期:
2024-05-30

文章信息/Info

Title:
Implementation Status and Policy Optimization of Centralized Volume-based Procurement of Psychotropic Drugs
作者:
徐 源1; 金春林1; 宋 捷1; 杨山石1
1.上海市卫生和健康发展研究中心（上海市医学科学技术情报研究所），上海 200031
Author(s):
XU Yuan;  JIN Chunlin;  SONG Jie;  YANG Shanshi
Shanghai Health Development Research Center(Shanghai Medical Information Center), Shanghai 200031, China
关键词:
集中带量采购; 精神类药品; 采购管理
Keywords:
entralized volume-based procurement;  psychotropic drugs;  procurement management
分类号:
R95
文献标志码:
A
摘要:
目的：分析精神类药品集中带量采购执行情况和存在问题，为政策完善提供参考建议。方法：采用文献分析法综述精神类药品的特殊性以及采购、使用风险，描述性分析草酸艾司西酞普兰片、帕罗西汀片在医院端和零售端的销售量和销售结构。结果：前八批国家集中带量采购共纳入25种精神类药品，基本覆盖常用药品，中选产品销售量上升，未中选仿制药市场份额逐渐被替代，未中选原研药份额变化不大；仿制药替换管理尚不完善，国家层面尚未出台针对精神类药品集中带量采购的特殊管理政策。结论：国家药品集中带量采购在政策设计层面要慎重纳入高风险精神类药品，采购量约定实行特殊药品特殊设置，并建立全链条质量管理闭环；在政策执行层面要设置过渡期，鼓励地方探索并完善配套政策；在临床使用层面要遵循患者个体化用药原则，谨慎使用替换，加强药物浓度和不良反应监测，并强化医患沟通。
Abstract:
Objective To analyze the implementation status and problems of centralized volume-based procurement of psychotropic drugs, and to provide reference suggestions for policy improvement. Methods Literature analysis was used to review the special characteristics of psychotropic drugs and the risks of procurement and use, and descriptive analysis was used to analyze the sales volume and sales structure of escitalopram oxalate tablets and paroxetine tablets in hospitals and retailers. Results A total of 25 psychotropic drugs were included in the first eight batches of national centralized volume-based procurement, basically covering commonly used drugs. The sales volume of the selected products increased, the market share of unsuccessful generic drugs was gradually replaced, and the share of unsuccessful originator drugs did not change much. The management of generic drug substitution was still imperfect, and the state has not yet issued a special management policy for centralized volume-based procurement of psychotropic drugs. Conclusion In national volume-based procurement of medicines, at the policy design level, high-risk psychotropic drugs should be carefully included, and special drug settings should be implemented in the procurement volume agreement, and a closed-loop quality management system should be established throughout the entire chain. At the policy implementation level, a transition period should be set up to encourage local governments to explore and improve supporting policies. At the clinical use level, it is necessary to follow the principle of individualized medication for patients, use replacement with caution, strengthen drug concentration and adverse reaction monitoring, and strengthen doctor-patient communication.

参考文献/References:

[1] 李凌江，陆林.精神病学（第3版）[M].北京:人民卫生出版社,2005:23-25.
[2] Yueqin HUANG,Yu WANG,Hong WANG,et al.Revalence of mental disorders in China:a cross-sectional epidemiological study[J]. The lancet.Psychiatry,2019,6(03):211-224.
[3] 江开达.精神疾病的特殊性与开展带量采购的思考[J].国际精神病学杂志，2021，48（03）：398-401.
[4] 潘锋.精神疾病是一个不容忽视的公共卫生问题——香山科学会议聚焦新型精神健康诊疗技术的挑战与机遇[J].中国当代医药，2023，30（11）：1-3.
[5] 木合塔尔·帕丽扎提，郭琪，袁晓劲，等.精神疾病的文化解读[J].中国健康心理学杂志，2024（01）：1-10.
[6] 郝伟，陆林.精神病学[M].北京：人民卫生出版社，2018.
[7] 唐倩影，刘代焱，任正伽.综合性三甲医院门诊精神疾病患者服药依从性影响因素分析[J].现代医药卫生，2022，38（10）：1663-1669.
[8] 杜娅慧，程祺，周蕾，等.疾病感知和治疗信心在精神疾病患者自我报告药物依从性中的作用分析[J].实用医院临床杂志，2023， 20（05）：91-94.
[9] Bressington D,Mui J,Gray R.Factors associated with antipsychotic medication adherence in community-based patients with schizo- phrenia in Hong Kong:A cross sectional study[J/OL].International Journal of Mental Health Nursing, 2013, 22(01): 35-46.
[10] 陈志东.窄治疗指数药物的多样性及安全用药建议[J].上海医药，2019（13）：29-35.
[11] Liang BA,Mackey TK,Lovett KM.Illegal“No Prescription” Internet Access to Narrow Therapeutic Index Drugs[J].Clin Ther,2013,35(05)：694-700.
[12] 程增江.窄治疗指数药物目录建立与特别监管探讨[J].中国食品药品监管，2020（05）：30-37.
[13] 潘锋.精神疾病是一个不容忽视的公共卫生问题——香山科学会议聚焦新型精神健康诊疗技术的挑战与机遇[J].中国当代医药，2023，30（11）：1-3.
[14] 马春梅，陈凤，刘倩.心理护理与语言沟通对精神疾病患者的影响[J/OL].心理月刊，2023，18（08）：175-177.
[15] 宿凌，黄文龙.完善我国药品零售企业处方监管法律的建议[J].医药导报，2011，30（03）：403-404.
[16] ChihWei H,ShengYu L,YaoHsu Y,et al.Brand-Name Antidepressants Outperform Their Generic Counterparts in Preventing Hospitalization for Depression:The Real-World Evidence from Taiwan[J].International Journal of Neuropsychopharmacology,2020,23(10):653-661.
[17] 赵滨.奥氮平对首发精神分裂症病患心电图的影响[J].中国药物与临床，2019，19（07）：1113-1115.
[18] 刘文夏，马俊，杨照，等.中国仿制药替代影响因素分析——基于“4+7”带量采购精神科用药患者角度[J].中国药学（英文版）,2023，32（04）：317-321.

相似文献/References:

[1]郑洋洋,丁锦希,李佳明,等.高值耗材实施集中带量采购的主要障碍及对策研究[J].卫生经济研究,2021,38(4):35.
　ZHENG Yang-yang,DING Jin-xi,LI Jia-ming,et al.Research on the Main Obstacles and Countermeasures of Centralized Quantity Purchase of High Value Medical Consumables[J].Journal Press of Health Economics Research,2021,38(06):35.
[2]周菁菁,谈在祥.国家组织冠脉支架集中带量采购的实施情况及建议[J].卫生经济研究,2021,38(11):3.
　ZHOU Jing-jing,TAN Zai-xiang.Implementation and Suggestions of Centralized Volume-based Procurement of Coronary Stent by National Organization[J].Journal Press of Health Economics Research,2021,38(06):3.
[3]赵予涵,林燕铭,谭艳芬.高值医用耗材治理背景下老年性白内障手术费用研究[J].卫生经济研究,2022,39(1):40.
　ZHAO Yu-han,LIN Yan-ming,TAN Yan-fen.Study on the Cost of Senile Cataract Surgery Under the High-value Medical Consumables Governance[J].Journal Press of Health Economics Research,2022,39(06):40.
[4]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(06):1.
[5]蒋范黎,肖 月,赵羽西,等.集采背景下经皮冠脉支架植入术成本测算及建议[J].卫生经济研究,2022,39(5):4.
　JIANG Fan-li,XIAO Yue,ZHAO Yu-xi,et al.The Cost Calculation and Analysis of Percutaneous Coronary Intervention under the Background of Centralized Procurement of Stents[J].Journal Press of Health Economics Research,2022,39(06):4.
[6]罗婷婷,王秀英,吴伟旋,等.医院不计价及打包收费耗材的管理现状及对策[J].卫生经济研究,2022,39(5):91.
　LUO Ting-ting,WANG Xiu-ying,WU Wei-xuan,et al.Management Status and Improvement Suggestions of Non-priced and Packaged Charging Consumables[J].Journal Press of Health Economics Research,2022,39(06):91.
[7]黄晓青,王煜昊,王丽娜,等.医用耗材集采背景下按病种分值付费优化方案研究 ——以冠状动脉支架为例[J].卫生经济研究,2022,39(10):16.
　HUANG Xiaoqing,WANG Yuhao,WANG Lina,et al.Research on Policy Optimization of Diagnosis-Intervention Packet Based the Volume-Based Procurement of Medical Comsumables ——Taking Coronary Stents as an Example[J].Journal Press of Health Economics Research,2022,39(06):16.
[8]孙李丽,毛 英,张馨怡,等.国家集中带量采购冠脉支架对住院费用的影响研究[J].卫生经济研究,2023,40(5):55.
　SUN Lili,MAO Ying,ZHANG Xinyi,et al.Study on the Effect of National Centralized Volume-based Procurement of Coronary Stents on Hospitalization Costs[J].Journal Press of Health Economics Research,2023,40(06):55.
[9]李 洁,周胜男,孙源源.基于政策工具理论的中成药集中带量采购政策设计研究[J].卫生经济研究,2023,40(6):13.
　LI Jie,ZHOU Shengnan,SUN Yuanyuan.Study on the Policy Design of Centralized Volume-based Procurement of Chinese Patent Medicine Based on the Policy Tools Theory[J].Journal Press of Health Economics Research,2023,40(06):13.
[10]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7.
　XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(06):7.

更新日期/Last Update: 2024-05-30